BB
BBIO
HealthcareBridgeBio Pharma, Inc.
Biotechnology
Total Trades
6
Unique Traders
1
Purchases / Sales
6/0
News Articles
5
Trading History
| Date | Politician | Asset | Action | Amount | Trade Price | 30D Price | 1M Return | Alpha | 1M Prediction |
|---|---|---|---|---|---|---|---|---|---|
Apr 29, 2026 |  Gilbert CisnerosD | Stock | Buy | $1,001 - $15,000 | $70.94 | N/A | N/A | N/A | |
Mar 19, 2026 | Gilbert CisnerosD | Stock | Buy | $1,001 - $15,000 | $70.07 | $76.75 | +9.5% | +1.6% | |
Mar 18, 2026 | Gilbert CisnerosD | Stock | Buy | $1,001 - $15,000 | $70.12 | $76.75 | +9.5% | +1.8% | |
Mar 3, 2026 | Gilbert CisnerosD | Stock | Buy | $1,001 - $15,000 | $64.53 | $73.15 | +13.4% | +16.7% | |
Sep 22, 2025 | Gilbert CisnerosD | Stock | Buy | $1,001 - $15,000 | $51.54 | $53.24 | +3.3% | +3.2% | |
Aug 8, 2025 | Gilbert CisnerosD | Stock | Buy | $1,001 - $15,000 | $46.58 | $53.38 | +14.6% | +13.0% |
Recent News
BridgeBio to Participate in May and June Investor Conferences
Finnhub-Invalid Date
BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition
SeekingAlpha-Invalid Date
BridgeBio Pharma's Acoramidis Receives Marketing Authorization From Brazil's Health Regulatory Agency To Treat Transthyretin Amyloidosis
Benzinga-Invalid Date
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
Finnhub-Invalid Date
BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE
Finnhub-Invalid Date